Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
74 hedge funds and large institutions have $88.5M invested in Generation Bio in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 19 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.56% less ownership
Funds ownership: 8.68% → 8.12% (-0.56%)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
1% less funds holding
Funds holding: 75 → 74 (-1)
59% less capital invested
Capital invested by funds: $217M → $88.5M (-$128M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.52M |
| 2 |
Morgan Stanley
New York
|
+$2.83M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.12M |
| 4 |
Millennium Management
New York
|
+$1.26M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$819K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$13.3M |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$6.31M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.37M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.88M |
| 5 |
JP Morgan Chase
New York
|
-$1.96M |
GBIO Hedge Fund Activity: Q4 2023 in Review
74 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q4 2023, worth a combined $88.5M — down 59% from $217M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of GBIO and 18 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 32 added.
The largest buyer was Bank of America, adding an estimated $3.52M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $13.3M sold.
- 74 institutional investors held Generation Bio (GBIO) as of Q4 2023, down from 75 in Q3 2023.
- Funds reported $88.5M of Generation Bio stock for Q4 2023, down 59% quarter-over-quarter.
- 18 funds opened new Generation Bio positions in Q4 2023 and 19 closed out, a net change of -1 holder.
- The largest Generation Bio buyer in Q4 2023 was Bank of America, an estimated $3.52M added.
- The largest Generation Bio seller in Q4 2023 was T. Rowe Price Investment Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q4 2023.